Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Walter Reed Army Medical Center
• Treatments: Brimonidine Tartrate; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

• Patients not meeting above stated age criteria

• Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)

• History of serious ocular, neurological, cardiovascular disease

• History of severe systemic disease

• History of arrhythmias or high blood pressure

• Patients currently taking any type of ocular or systemic medications except multivitamins.

• Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.